Literature DB >> 8550765

The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test.

D H Streeten1, G H Anderson, M M Bonaventura.   

Abstract

Despite unequivocal published evidence that patients with subnormal hypothalamic-pituitary-adrenal (HPA) function may respond normally to ACTH, such normal results are still considered reliable indications of unimpaired HPA function. This view was tested in four patients with clinical features suggesting corticotropin deficiency, in whom cosyntropin (0.25 mg, i.v.) raised serum cortisol above 560 nmol/L (20 micrograms/dL) at 1 h. All four patients had subnormal responses to metyrapone and excellent persistent improvement during subsequent glucocorticoid therapy. Serum cortisol concentrations 1 h after cosyntropin treatment in these patients closely resembled cortisol concentrations 1 h after uncomplicated cholecystectomy in six other patients. However, the rapid ACTH test in the patients with hypopituitarism failed to indicate whether more prolonged stimulation by ACTH or their endogenous stress would stimulate the normal continuing rise in serum cortisol, which reached 1358 +/- 170 nmol/L (+/- SE) 5 h after the incision in the cholecystectomized patients. As the three hypocorticotropic patients who were recognizably stressed had unstressed serum cortisol levels despite persistent adrenocortical reserve (shown by their ACTH responses) and recovered during glucocorticoid therapy, the ACTH test, if interpreted to indicate normal HPA function, would probably have had disastrous consequences. We conclude that a normal response to the rapid ACTH test can be dangerously misleading, particularly in incomplete ACTH deficiency states.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550765     DOI: 10.1210/jcem.81.1.8550765

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Repetitive graded ACTH stimulation test for adrenal insufficiency.

Authors:  T S Huang; Y D Jiang
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

2.  The diagnosis of secondary adrenal insufficiency: low dose vs high dose ACTH stimulation test.

Authors:  A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

Review 3.  Diagnosis and treatment of ACTH deficiency.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

4.  Total and free cortisol levels during 1 μg, 25 μg, and 250 μg cosyntropin stimulation tests compared to insulin tolerance test: results of a randomized, prospective, pilot study.

Authors:  Seenia Peechakara; James Bena; Nigel J Clarke; Michael J McPhaul; Richard E Reitz; Robert J Weil; Pablo Recinos; Laurence Kennedy; Amir H Hamrahian
Journal:  Endocrine       Date:  2017-07-20       Impact factor: 3.633

Review 5.  Medical management of hypopituitarism in patients with pituitary adenomas.

Authors:  Baha M Arafah
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

6.  Do topical ophthalmic corticosteroids suppress the hypothalmic-pituitary-adrenal axis in post-penetrating keratoplasty patients?

Authors:  S S Sandhu; J M Smith; M Doherty; A James; F C Figueiredo
Journal:  Eye (Lond)       Date:  2012-02-17       Impact factor: 3.775

7.  Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease.

Authors:  G Aimaretti; C Baffoni; L Di Vito; S Grottoli; D Gaia; V Gasco; R Giordano; Z Zadik; F Camanni; E Ghigo; E Arvat
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

Review 8.  Isolated corticotrophin deficiency.

Authors:  Massimiliano Andrioli; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

9.  Acylated ghrelin as provocative test for the diagnosis of ACTH deficiency in patients with hypothalamus-pituitary disease.

Authors:  Valentina Gasco; Alessandro Berton; Mirko Parasiliti Caprino; Ioannis Karamouzis; Mauro Maccario; Ezio Ghigo; Silvia Grottoli
Journal:  Endocrine       Date:  2014-12-09       Impact factor: 3.633

10.  Adrenocortical suppression increases the risk of relapse in nephrotic syndrome.

Authors:  Asiri S Abeyagunawardena; Peter Hindmarsh; Richard S Trompeter
Journal:  Arch Dis Child       Date:  2007-02-06       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.